Artelo Biosciences Inc. (ARTL)
NASDAQ: ARTLHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ARTL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.85M
- EPS (TTM)
- -$136.26
- Dividend yield
- None
- 52-week range
- 3.33 – 179.19
- Day range
- 3.37 – 3.51
- Volume / Avg
- 27.21K / 480.72K
- Beta
- —
- Shares outstanding
- 547.77K
52-week range
ARTL stock today
Artelo Biosciences (ARTL) closed at $3.37 on Oct 8, down 1.17% (-$0.04), versus the S&P 500's 0.47% decline. Trading was light, with 27.21K shares changing hands, about 6% of the average daily volume. Shares are 98.1% below their 52-week high of $179.19 and 1.2% above the 52-week low of $3.33, near the bottom of the past year's range.
Artelo Biosciences has posted a net loss over the last twelve months (EPS of -$136.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Artelo Biosciences
Company profileArtelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Gregory D. Gorgas M.B.A.
- Headquarters
- Solana Beach, CA
- Employees
- 7
- Website
- artelobio.com
Artelo Biosciences peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.792 | -6.80% | $1.88M | vs ARTL |
| VBIOValion Bio Inc. | 2.21 | +0.91% | $1.96M | vs ARTL |
| EDVAEndovia Health Sciences Inc. | 0.1599 | -3.09% | $1.77M | vs ARTL |
| CRISCuris Inc. | 0.7094 | -3.69% | $1.72M | vs ARTL |
| OGENOragenics Inc. | 0.463 | -7.38% | $2.09M | vs ARTL |
| SCNIScinai Immunotherapeutics Ltd. ADR | 1.21 | +7.08% | $1.64M | vs ARTL |
| GNPXGenprex Inc. | 2.75 | +4.96% | $2.25M | vs ARTL |
| TCRTAlaunos Therapeutics Inc. | 0.781 | -6.70% | $2.29M | vs ARTL |
Indexes, lists and sector
Appears in lists
Artelo Biosciences stock FAQ
What is Artelo Biosciences's stock price today?
ARTL last traded at $3.37 as of Oct 8, 4:00 PM EDT, down 1.17% on the day. Prices are delayed at least 15 minutes.
Who is Artelo Biosciences's CEO?
Mr. Gregory D. Gorgas M.B.A. is the chief executive officer of Artelo Biosciences Inc., which has about 7 employees.
What is the ARTL 52-week high?
The 52-week high for ARTL is $179.19 and the 52-week low is $3.33. The stock is currently 98.1% below its high.